KYAN Technologies - Revision history

C at 08:41, 27 December 2025

2025-12-27T08:41:42Z

← Older revision		Revision as of 08:41, 27 December 2025
Line 17:		Line 17:

	==Traction==		==Traction==
	KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web \|last=admin \|date=2023-05-29 \|title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients \|url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref>. Their facility is located in [[Temasek Life ~~Science~~ Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.		KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web \|last=admin \|date=2023-05-29 \|title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients \|url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref>. Their facility is located in [[Temasek Life Sciences Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.

	In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web \|last=admin \|date=2025-02-05 \|title=KYAN Technologies announces collaboration with OncoCare Malaysia \|url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref>.		In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web \|last=admin \|date=2025-02-05 \|title=KYAN Technologies announces collaboration with OncoCare Malaysia \|url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref>.

C: /* Traction */

2025-12-20T23:30:09Z

Traction

← Older revision		Revision as of 23:30, 20 December 2025
Line 1:		Line 1:
	~~{{Draft}}~~
	{{Infobox Startup		{{Infobox Startup
	\|logo=Kyan therapeutics logo.jpg		\|logo=Kyan therapeutics logo.jpg
Line 10:		Line 9:
	\|headquarters=Singapore		\|headquarters=Singapore
	}}		}}
	KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development.		KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development in oncology.

	==Technology==		==Technology==
	KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based ~~platofrm~~ to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web \|title=Optim.AI™ for Clinicians \|url=https://kyantechnologies.com/optimai-clinical-decision-support/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref> across 20+ different cancer types.		KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platform to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web \|title=Optim.AI™ for Clinicians \|url=https://kyantechnologies.com/optimai-clinical-decision-support/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref> across 20+ different cancer types.

	The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web \|title=Translational Biobank \|url=https://kyantechnologies.com/translational-biobank/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en}}</ref>.		The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web \|title=Translational Biobank \|url=https://kyantechnologies.com/translational-biobank/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en}}</ref>.

	==Traction==		==Traction==
	~~List notable customers or partnerships here~~. ~~Awards should not be listed here~~, ~~but under "Accolades" instead~~		KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web \|last=admin \|date=2023-05-29 \|title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients \|url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref>. Their facility is located in [[Temasek Life Science Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.

	==~~Accolades~~==		In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web \|last=admin \|date=2025-02-05 \|title=KYAN Technologies announces collaboration with OncoCare Malaysia \|url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref>.
	~~List awards received by~~ the startup ~~here~~.
			In March 2025, KYAN Technologies entered a collaboration with Mayo Clinic Laboratories to validate and provide the startup's testing platform across the United States<ref>{{Cite web \|last=admin \|date=2025-03-13 \|title=Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testing \|url=https://kyantechnologies.com/mayo-clinic-laboratories-and-kyan-technologies-enter-a-collaboration-to-expand-patients-access-to-cancer-testing/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref>.

	==Funding==		==Funding==
	KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web \|last=Chong \|first=Jinn Xiung \|title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round \|url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round \|url-status=live}}</ref>.{{Startup/Funding history}}		KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web \|last=Chong \|first=Jinn Xiung \|title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round \|url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round \|url-status=live}}</ref>{{Startup/Funding history}}

	~~== See also ==~~
	* List any other pages directly relevant to {{PAGENAME}}

	== References ==		== References ==
	{{Reflist}}		{{Reflist}}

C: /* Technology */

2025-12-20T23:14:11Z

Technology

← Older revision		Revision as of 23:14, 20 December 2025
Line 13:		Line 13:

	==Technology==		==Technology==
	KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web \|title=Optim.AI™ for Clinicians \|url=https://kyantechnologies.com/optimai-clinical-decision-support/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref> across 20+ ~~differnt~~ cancer types.		KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web \|title=Optim.AI™ for Clinicians \|url=https://kyantechnologies.com/optimai-clinical-decision-support/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref> across 20+ different cancer types.

			The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web \|title=Translational Biobank \|url=https://kyantechnologies.com/translational-biobank/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en}}</ref>.

	==Traction==		==Traction==
Line 22:		Line 24:

	==Funding==		==Funding==
	~~Describe the startup's~~ funding ~~history here~~. ~~Include investors in the table below~~.{{Startup/Funding history}}		KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web \|last=Chong \|first=Jinn Xiung \|title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round \|url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round \|url-status=live}}</ref>.{{Startup/Funding history}}

	== See also ==		== See also ==

C at 15:13, 20 December 2025

2025-12-20T15:13:34Z

← Older revision		Revision as of 15:13, 20 December 2025
Line 10:		Line 10:
	\|headquarters=Singapore		\|headquarters=Singapore
	}}		}}
	~~A brief overview of {{PAGENAME}} here~~		KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development.

	==Technology==		==Technology==
	~~Describe the underlying science and~~ technology ~~of the startup here. Ideally~~, ~~it should provide~~ a ~~layman introduction of any key differentiators~~ and/~~or novel or proprietary scientific breakthroughs being commercialised by the startup~~.		KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web \|title=Optim.AI™ for Clinicians \|url=https://kyantechnologies.com/optimai-clinical-decision-support/ \|access-date=2025-12-20 \|website=KYAN Technologies \|language=en-US}}</ref> across 20+ differnt cancer types.

	==Traction==		==Traction==

C: Created page with "{{Draft}} {{Infobox Startup |logo=Kyan therapeutics logo.jpg |status=Active |website=https://kyantechnologies.com/ |vertical=Medtech, Biotechnology |trl=Deployment (TRL 7-8) |latest_funding=Pre-Series A |founding_year=2016 |headquarters=Singapore }} A brief overview of {{PAGENAME}} here ==Technology== Describe the underlying science and technology of the startup here. Ideally, it should provide a layman introduction of any key differentiators and/or novel or propriet..."

2025-12-20T14:48:35Z

Created page with "{{Draft}} {{Infobox Startup |logo=Kyan therapeutics logo.jpg |status=Active |website=https://kyantechnologies.com/ |vertical=Medtech, Biotechnology |trl=Deployment (TRL 7-8) |latest_funding=Pre-Series A |founding_year=2016 |headquarters=Singapore }} A brief overview of {{PAGENAME}} here ==Technology== Describe the underlying science and technology of the startup here. Ideally, it should provide a layman introduction of any key differentiators and/or novel or propriet..."

New page

{{Draft}}
{{Infobox Startup
|logo=Kyan therapeutics logo.jpg
|status=Active
|website=https://kyantechnologies.com/
|vertical=Medtech, Biotechnology
|trl=Deployment (TRL 7-8)
|latest_funding=Pre-Series A
|founding_year=2016
|headquarters=Singapore
}}
A brief overview of {{PAGENAME}} here

==Technology==
Describe the underlying science and technology of the startup here. Ideally, it should provide a layman introduction of any key differentiators and/or novel or proprietary scientific breakthroughs being commercialised by the startup.

==Traction==
List notable customers or partnerships here. Awards should not be listed here, but under "Accolades" instead

==Accolades==
List awards received by the startup here.

==Funding==
Describe the startup's funding history here. Include investors in the table below.{{Startup/Funding history}}

== See also ==
* List any other pages directly relevant to {{PAGENAME}}

== References ==
{{Reflist}}